Known targets — ChEMBL curated mechanism
ACEADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ATP4AATP4BAXLBTKCACNA1CCACNA1DCACNA1FCACNA1SCCR5CHRM2CHRM3CPT1BCPT2DPP4DRD1DRD2EGFRERBB2ERBB4FLT3HRH1HRH3HTR1AHTR2AHTR2BHTR2CHTR4JAK1JAK2JAK3KCNH2KMT2AMAP2K1MAP2K2MEN1MLNRMPLMTORPPIK3CAPIK3CBPIK3CDPIK3CGPIK3R1PIK3R2PIK3R3PIK3R5PLK4PPARGRENS1PR1SLC6A2SLC6A3SLC6A4SMOTYK2atpAatpBatpCatpDatpEatpFatpFHatpGpol
The experimentally established mechanism targets of Fumaric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 known ✓ | P23975 | 8/20 | 0.45 |
| ▸ | SLC6A4 known ✓ | P31645 | 8/20 | 0.45 |
| ▸ | SLC6A3 known ✓ | Q01959 | 3/20 | 0.42 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.39 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.39 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.39 |
| ▸ | ADRA1A known ✓ | P35348 | 1/20 | 0.39 |
| ▸ | HTR2B known ✓ | P41595 | 1/20 | 0.39 |
| ▸ | ADRA2C known ✓ | P18825 | 1/20 | 0.39 |
| ▸ | SCN9A | Q15858 | 9/20 | 0.54 |
| ▸ | SCN5A | Q14524 | 5/20 | 0.54 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.53 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.53 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.53 |
| ▸ | MKNK1 | Q9BUB5 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fumaric Acid SCHEMBL3155063 | 1.00 | SCN9A (0.54) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Maleic Acid SCHEMBL3155055 | 1.00 | SCN9A (0.54) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Fumaric Acid SCHEMBL3161163 | 0.94 | SCN9A (0.46) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Maleic Acid SCHEMBL3161156 | 0.94 | SCN9A (0.46) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Fumaric Acid SCHEMBL3143224 | 0.94 | SCN9A (0.51) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Maleic Acid SCHEMBL3143216 | 0.94 | SCN9A (0.51) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Fumaric Acid SCHEMBL3161160 | 0.94 | SCN9A (0.46) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| Fumaric Acid SCHEMBL3143229 | 0.94 | SCN9A (0.51) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| SCHEMBL3150759 | 0.93 | SCN9A (0.58) | SCN9ASCN5ASCN2ASCN3ASCN8A | |
| SCHEMBL3150767 | 0.93 | SCN9A (0.58) | SCN9ASCN5ASCN2ASCN3ASCN8A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1828182-B1 | THERAPEUTIC PYRAZOLO[3,4-B]PYRIDINES AND INDAZOLES | WARNER LAMBERT CO (US) | 2010-03-10 | — | — | EP | disclosed |
| US-7485636-B2 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | PFIZER INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-20080293715-A1 | Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles | WARNER LAMBERT COMPANY LLC (US) | 2008-11-27 | — | — | US | disclosed |
| US-7423054-B2 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER LAMBERT COMPANY LLC (US) | 2008-09-09 | — | — | US | disclosed |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-09-28 | — | — | US | disclosed |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | WARNER-LAMBERT COMPANY LLC | 2006-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293715-A1 | Therapeutic Pyrazolo[3,4-b]Pyridines and Indazoles | P2RX3, P2RX4, ACHE | SLC6A2 355/4885SLC6A4 92/4885SLC6A3 87/4885 |
| US-20060116376-A1 | Therapeutic pyrazolo[3,4-B]pyridines and indazoles | P2RX3, P2RX4, ACHE | SLC6A2 355/4885SLC6A4 92/4885SLC6A3 87/4885 |
| US-20060217376-A1 | Therapeutic pyrazolo[3,4-b]pyridines and indazoles | P2RX3, P2RX4, ACHE | SLC6A2 355/4885SLC6A4 92/4885SLC6A3 87/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.